Patients treated with pembrolizumab or ipilimumab may also develop fulminant myocarditis with fatal outcomes, however in CTLA-4/PD-1 blocking agents association studies show an increase in myocarditis events compared to monotherapies (15). This evidence concerns the gene CTLA4 and myocarditis.